Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1000 of 1317 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/29/24
End: 06/30/28
Due: 06/30/29
Phase: N/A
Priority: Normal
Start: 03/31/13
End: 09/30/13
Due: 09/30/14
Phase: N/A
Priority: Normal
Start: 01/31/13
End: 10/31/14
Due: 10/31/15
Phase: N/A
Priority: Normal
Start: 12/31/13
End: 10/31/16
Due: 10/31/17
Phase: N/A
Priority: Normal
Start: 07/05/11
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 03/23/22
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 07/31/14
End: 03/31/15
Due: 03/31/16
Phase: N/A
Priority: Normal
Start: 08/29/12
End: 08/28/13
Due: 08/28/14
Phase: N/A
Priority: Normal
Start: 04/21/19
End: 08/19/22
Due: 08/19/23
Phase: N/A
Priority: Normal
Start: 02/29/12
End: 10/31/12
Due: 10/31/13
Phase: N/A
Priority: Normal
Start: 09/12/16
End: 02/26/18
Due: 02/26/19
Phase: N/A
Priority: Normal
Start: 06/01/21
End: 02/28/25
Due: 02/28/26
Phase: N/A
Priority: Normal
Start: 07/20/23
End: 01/30/25
Due: 01/30/26
Phase: N/A
Priority: Normal
Start: 05/31/14
End: 12/31/14
Due: 12/31/15
Phase: N/A
Priority: Normal
Start: 06/30/14
End: 12/07/15
Due: 12/07/16
Phase: N/A
Priority: Normal
Start: 03/17/22
End: 02/29/24
Due: 02/28/25
Phase: N/A
Priority: Normal
Start: 11/08/17
End: 11/23/18
Due: 11/23/19
Phase: N/A
Priority: Normal
Start: 10/20/14
End: 10/10/15
Due: 10/10/16
Phase: N/A
Priority: Normal
Start: 02/28/25
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 01/03/19
End: 06/30/24
Due: 06/30/25
A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients
Phase: N/A
Priority: Normal
Start: 04/08/20
End: 01/26/25
Due: 01/26/26
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 07/31/07
End: 01/31/10
Due: 01/31/11
Phase: N/A
Priority: Normal
Start: 10/10/23
End: 08/22/28
Due: 08/22/29
Phase: N/A
Priority: Normal
Start: 03/31/19
End: 04/30/20
Due: 04/30/21